Advertisement

Pruritus pp 183-187 | Cite as

Psoriasis

  • Adam ReichEmail author
  • Jacek C. Szepietowski
Chapter

Abstract

Pruritus is an important symptom of inflammatory skin diseases as local inflammatory mechanisms may induce neurogenic inflammation and subsequent itch. Mild to severe pruritus accompanies numerous inflammatory skin disorders including, but not limited to atopic dermatitis, eczema, psoriasis, pemphigoid or lichen planus. The frequency of pruritus in skin diseases may vary depending on the entity and studied population. Many aspects of pruritus in inflammatory cutaneous conditions, like psoriasis still remains unclarified and further clinical and molecular studies on itching have to be performed in the near future to elaborate more specific and efficacious antipruritic therapies.

Keywords

Psoriasis Neurogenic inflammation Treatment Dermatologic pruritus 

References

  1. 1.
    Newbold PCH. Pruritus in psoriasis. In: Farber EM, Cox AJ, editors. Psoriasis: proceedings of the second international symposium. New York: Yorke Medical Books; 1997. p. 334–6.Google Scholar
  2. 2.
    Szepietowski JC, Reich A, Wiśnicka B. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croat. 2002;10:221–6.PubMedGoogle Scholar
  3. 3.
    Gupta MA, Gupta AK, Kirby S, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol. 1988;124:1052–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Reich A, Szepietowski JC, Wiśnicka B, et al. Does stress influence itching in psoriatic patients? Dermatol Psychosom. 2003;4:151–5.CrossRefGoogle Scholar
  6. 6.
    Chang S-E, Han S-S, Jung H-J, et al. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156:1272–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Reich A, Orda A, Wiśnicka, et al. Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol (Stockh). 2007;87:299–304.CrossRefGoogle Scholar
  8. 8.
    Wiśnicka B, Szepietowski JC, Reich A, et al. Histamine, substance P and calcitonin gene-related peptide plasma concentration and pruritus in patients suffering from psoriasis. Dermatol Psychosom. 2004;5:73–8.CrossRefGoogle Scholar
  9. 9.
    Remröd C, Lonne-Rahm S, Nordlind K. Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res. 2007;299:85–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Reich A, Hrechorow E, Szepietowski JC. Negative influence of itching on psoriatic patients’ well-being. Acta Derm Venereol (Stockh). 2007;87:478–9.CrossRefGoogle Scholar
  11. 11.
    Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70:390–1.CrossRefPubMedGoogle Scholar
  12. 12.
    Reich A, Welz-Kubiak K, Rams L. Apprehension of the disease by patients suffering from psoriasis. Postepy Dermatol Alergol. 2014;31:289–93.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol. 2015;29:1114–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu B, Edson-Heredia E, Guo J, et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol. 2014;171:1215–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Janowski K, Steuden S, Bogaczewicz J. Clinical and psychological characteristics of patients with psoriasis reporting various frequencies of pruritus. Int J Dermatol. 2014;53:820–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Remröd C, Sjöström K, Svensson Å. Pruritus in psoriasis: a study of personality traits, depression and anxiety. Acta Derm Venereol. 2015;95:439–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Eedy DJ, Johnston CF, Shaw, et al. Neuropeptides in psoriasis: an immunocytochemical and radioimmunoasay study. J Invest Dermatol. 1991;96:434–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Naukkarinen A, Harvima I, Paukkonen K, et al. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res. 1993;285:341–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Chan J, Smoller BR, Raychauduri SP, et al. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res. 1997;287:611–6.CrossRefGoogle Scholar
  20. 20.
    Jiang W-Y, Raydchaudhuri SP, Farber EM. Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol. 1998;37:572–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Raychaudhuri SP, Jiang W-Y, Farber EM. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol (Stockh). 1998;78:84–6.CrossRefGoogle Scholar
  22. 22.
    Staniek V, Doutremepuich J-D, Schmitt D, et al. Expression of substance P receptors in normal and psoriatic skin. Photobiology. 1999;67:51–4.Google Scholar
  23. 23.
    Steinhoff M, McGregor GP, Radleff-Schlimme A, et al. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept. 1999;80:49–55.CrossRefPubMedGoogle Scholar
  24. 24.
    He Y, Ding G, Wang X, et al. Calcitonin gene-related peptide in Langerhans cells in psoriatic plaque lesions. Chin Med J. 2000;113:747–51.PubMedGoogle Scholar
  25. 25.
    Reich A, Orda A, Wiśnicka B, et al. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol. 2007;16:421–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149:718–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Bernstein JE, Parish LC, Rapaport M, et al. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986;15:504–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol. 1993;29:438–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Kou K, Nakamura F, Aihara M, et al. Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin. Acta Derm Venereol. 2012;92:521–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Krzyżanowska M, Muszer K, Chabowski K, Reich A. Assessment of the sensory threshold in patients with atopic dermatitis and psoriasis. Postepy Dermatol Alergol. 2015;32:94–100.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Madej A, Reich A, Orda A, et al. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol. 2007;21:72–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18:227–33.PubMedGoogle Scholar
  33. 33.
    Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol. 1999;140:887–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50:889–91.CrossRefPubMedGoogle Scholar
  35. 35.
    Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95:542–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015;26:19–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2016

Authors and Affiliations

  1. 1.Department of Dermatology, Venereology and AllergologyWroclaw Medical UniversityWroclawPoland

Personalised recommendations